CSV October 31, 2022 through October 31, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CALCIUM	IM	*USP42–NF37*	666	30-Aug-2019	1-Sep-2019	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CARBONATE	PURITIES/*Limit of Magnesium and Alkali Salts*							*Sample solution*: 1.0 g to: *Sample*: 1.0 g
FEXOFENADINE HYDROCHLORIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official November 01, 2018)*	Online	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.
PHARMACEU	19. MEAN	*USP42–NF37*	7831	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In *19.4 Example*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TICAL CALCULATIONS IN PHARMACY PRACTICE	KINETIC TEMPERATURE							*Calculations of MKT for CRT Storage Evaluation/Example 3—Calculation of Annual MKTStep 3*: Change 3.354 to: 3.340 AND In *Step 4*: Change 2.795 to: 2.783 AND In *Step 5*: Change ?33.511 to: ?33.515 AND In *Step 6*: Change 298.410 to: 298.372
G49	CHROMATOG	*First*	8127	28-Jul-2019	20-Apr-2019	*USP42–NF37*	*First*	Add

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	RAPHIC CO LUMN S/*Packings*	*Supplement to USP40–NF35*					*Supplement to USP41–NF36*	G49—Dimethylpolysiloxane with chiral building block containing D- or L-valine as chiral agent (for amino acids).
TIAGABINE HYDROCHLORIDE	IM PURITIES/*Limit of (S)-(+) Isomer*/*Mobile phase*	*First Supplement to USP42–NF37*	8823	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change Hexane, to: *n*-Hexane, AND Change hexane to: *n*-hexane
BUSPIRONE HYDROCHLORIDE TABLETS	IDENTIFICATION/*B.*	*USP42–NF37*	621	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change relative retention time to: retention time
GLUCAGON BIOIDENTITY TESTS	*B. In Vitro Cell-Based Bioidentity Test*	*USP42–NF37*	6478	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Standard stock solution*: Change 0.4 µg/mL to: 4 µg/mL
OXALIPLATIN INJECTION	IM PURITIES/*Limit of Oxalic*	*First Supplement to USP42–NF37*	8781	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Column*: Change L31

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Acid/ Chromatographic system							to: L81
ALUMINA, MAGNESIA, AND SIMETHICONE ORAL SUSPENSION	SPECIFIC TESTS/ *Microbial Enumeration Tests <61> and Tests for Specified Microorganisms <62>*	*USP42–NF37*	170	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change cfu/g to: cfu/mL
VALGANCICLOVIR HYDROCHLORIDE	*Related compounds*	*USP42–NF37*	4528	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In Column 2 of *Table 3*: Change Bis-valine easter of ganciclovir to: Bis-valine ester of ganciclovir
LAMOTRIGINE TABLETS FOR ORAL SUSPENSION	PERFORMANCE TESTS/ *Dissolution <711>/ Chromatographic procedure 1*	*First Supplement to USP42–NF37*	8720	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Buffer*: Change glacial acetic acid acid to: glacial acetic acid
BALANCES	REPEATABILITY	*First Supplement to USP42–NF37*	9011	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In all instances in paragraph 2: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								s_r to: s AND In paragraph 2: Change is found to be 0.0015, then M_{min} must be ? 0.3000 g or 300 mg. to: is found to be 0.00015, then M_{min} must be ? 0.30000 g or 300.00 mg.
CHLOROTHIAZIDE	*Selenium <291>*	*USP42–NF37*	942	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change 0.003%. to: NMT 0.003%.
BENAZEPRIL HYDROCHLORIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 1*	*First Supplement to USP42–NF37*	8644	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In the *Standard solution*: Change µg/mL to: µg/µL
TIAGABINE HYDROCHLORIDE	ASSAY/ *Procedure*	*First Supplement to USP42–NF37*	8823	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Analysis*: Change Result = (*R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U/R_S$) × (C_S/C_U) × $^?(M_{r1}/M_{r2})$ ×$_?$ (USP 1-Aug-2019) 100 to: Result = (R_U/R_S) × (C_S/C_U) × 100 AND Delete $^?M_{r1}$ = molecular weight of tiagabine hydrochloride, 412.00 M_{r2} = molecular weight of tiagabine hydrochloride monohydrate, 430.02$_?$ (USP 1-Aug-2019)
BUSPIRONE HYDROCHLORIDE	IDENTIFICATION/*B.*	*USP42–NF37*	618	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change relative retention time to: retention time
POWDERED MILK THISTLE EXTRACT	COMPOSITION/*Content of Silymarin*	*USP42–NF37*	5102	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Table 2*: Change Tsosilybin B

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Isosilybin B
LOVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP42–NF37*	8727	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Mobile phase*: Change Processed as directed in the *Assay* to: Proceed as directed in the *Assay*.
ALPROSTADIL	ASSAY/ *Procedure*	*USP42–NF37*	151	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *System suitability stock solution*: Change *Standard solution* to: *Standard stock solution*
IOVERSOL	CHEMICAL INFORMATION	*USP42–NF37*	2345	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change *N*,*N* ?-Bis(2,3-dihydrox ypro pyl)-5-*N* -(2-hydroxyethyl)glycol amido]-2 ,4,6-triiodoisoph thalamide. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								N,*N*’-Bis(2,3-dihydroxypropyl)-5-[*N*-(2-hydroxyethyl)glycolamido]-2,4,6-triiodoisophthalamide.
EPHEDRINE HYDROCHLORIDE	CHEMICAL INFORMATION	*First Supplement to USP42–NF37*	8682	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Add (1*R*,2*S*)-2-(Methylamino)-1-phenylpropan-1-ol hydrochloride;
ETIDRONATE DISODIUM	SPECIFIC TESTS/*Water Determination <921>*	*USP42–NF37*	1745	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Sample solution*: Change acetic acid to: glacial acetic acid
CHOLINE BITARTRATE	IM PURITIES/*Limit of Total Amines*/*System suitability*	*USP42–NF37*	4839	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Suitability requirements*: Change ?g/L. to: ?g/mL.
ACETAMINOPHEN ORAL SUSPENSION	ASSAY	*Second Supplement to USP41–NF36*	Online	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In the first *Procedure*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								?(Postponed on 1-Aug-2018) to:
VORICONAZOLE	IMPURITIES/ *Voriconazole Related Compounds C and D*	*USP42–NF37*	4601	28-Jun-2019	1-Jul-2019	*NA*	*NA*	?(RB 1-Aug-2018) In *System suitability solution*: Change 0.25 µg/mL of USP Voriconazole RS to: 0.25 µg/mL of USP Voriconazole RS in *Mobile phase*
SAW PALMETTO CAPSULES	IDENTIFICATION/*B. Presence of Sterols*	*USP42–NF37*	5198	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *System suitability stock solution B*: Change 2 mg/mL each of campesterol, stigmasterol,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and USP ?-Sitosterol RS, and 0.37 mg/mL of stigmastanol to: 0.37 mg/mL of stigmastanol and 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS in chloroform
POLYVINYL ALCOHOL	IDENTIFICATION	*USP42–NF37*	3566	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *B*: Change It meets the requirements in the test *Viscosity—Capillary Methods <911>*, *Viscosity—Rotational Methods <912>*, and *Viscosity—Rolling Ball Method <913>*. to: It meets the requirements in the test

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Viscosity—Capillary Methods <911>, *Viscosity—Rotational Methods <912>*, or *Viscosity—Rolling Ball Method <913>*.
CHOLINE CHLORIDE	IM PURITIES/*Limit of Total Amines*/*System suitability*	*USP42–NF37*	4841	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Suitability requirements*: Change ?g/L. to: ?g/mL.
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official November 01, 2018)*	Online	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Test 1*/*Tolerances* and *Test 3*/*Tolerances*: Change $[(C_{17}H_{19}NO_3)_2 \cdot H_2SO_4 \cdot 5H_2O)]$ to: $[(C_{17}H_{19}NO_3)_2 \cdot H_2SO_4 \cdot 5H_2O]$
ZONISAMIDE	IM PUR ITIES/*Organic Impurities*	*USP42–NF37*	4675	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Analysis*: Change C_U = concentration of zonisamide related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compound A in the *Sample solution* (mg/mL) to: C_U = concentration of zonisamide in the *Sample solution* (mg/mL)
CHITOSAN	ASSAY/*Degree of Deacetylation*	*USP42–NF37*	5663	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In the *Analysis*: Change Result = {1 ? [(7 × A_2)/(3 × A_1)] × 100 to: Result = {1 ? [(7 × A_2)/(3 × A_1)]} × 100
SODIUM BICARBONATE	IM PURITIES/ *Carbonate*	*USP42–NF37*	4019	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Analysis*: Change and promptly add 10 g of sodium bicarbonate to: and promptly add 10 g of Sodium Bicarbonate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SAW PALMETTO EXTRACT	COMPOSITION /*Content of Long-Chain Alcohols and Sterols*	*USP42–NF37*	5196	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *System suitability stock solution B*: Change 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS and 0.37 mg/mL of stigmastanol to: 0.37 mg/mL of stigmastanol and 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS in chloroform
REAGENTS AND REFERENCE TABLES	S OL UTIONS/*0.02 M Edetate Disodium VS*	*USP42–NF37*	6179	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Standardization*: Change previously dried at 100° to: previously dried at 110°
CEFTIOFUR SODIUM	IM PURITIES/*High*	*USP42–NF37*	859	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Molecular Weight Impurities							r_C = peak response of ceftiofur from the *Sample solution* (mg/mL) r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution* (mg/mL) to: r_C = peak response of ceftiofur from the *Sample solution* r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution*
DIPHENHYDRAMINE HYDROCHLORIDE AND IBUPROFEN CAPSULES	ASSAY/ *Procedure/ Chromatographic system/*	*USP42–NF37*	1402	31-May-2019	1-Jun-2019	*NA*	*NA*	Change *Identification test A*: Diode array, UV 200–400 nm to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Detectors							*Identification B*: Diode array, UV 200–400 nm
DULOXETINE DELAYED-RELEASE CAPSULES	ASSAY/ *Procedure*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Buffer A*: Change monobasic sodium phosphate to: monobasic potassium phosphate AND In *Buffer B*: Change monobasic sodium phosphate to: monobasic ammonium phosphate
LEVOCARNITINE	IMPURITIES/ *Enantiomeric Purity*	*USP42–NF37*	2541	31-May-2019	1-Jun-2019	*NA*	*NA*	In the second equation in *Analysis*: Change Result = (R_L ? P_B)/(P_A ? P_B) to: Result = (R_L ? *P*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_B)/(P_A$? $P_B) \times$ 100
TELMISARTAN TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4206	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Telmisartan Related Compound A RS: Change 1,7’-Dimethyl-2’-propyl-1*H*,3’*H*-2,5’-bibenzo[*d*]imidazole. $C_{19}H_{20}N_4$ 304.39 to: 1,7’-Dimethyl-2’-propyl-1*H*,3’*H*-2,5’-bibenzo[*d*]imidazole monohydrate. $C_{19}H_{20}N_4$? H_2O 322.41
LIQUID GLUCOSE	ASSAY/*Reducing Sugars*	*USP42–NF37*	5741	31-May-2019	1-Jun-2019	*NA*	*NA*	In the variable definition list in *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_U = concentration of dextrose equivalent to: C_U = concentration of Liquid Glucose
ROSUVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 3*	*Revision Bulletin (Official April 01, 2019)*	Online	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Medium*: Change (dissolve 63.0 of citric acid to: (dissolve 63.0 g of citric acid
DACTINOMYCIN	IDENTIFICATION/*A. Ultraviolet Absorption <197U>/ Acceptance criteria*	*USP42–NF37*	1203	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Absorptivity*: Change The absorptivity of the *Sample solution* at 445 nm is NLT 95.0% and NMT 103.0% that of the *Standard solution*. to: The absorptivity, calculated on the dried basis, of the *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution at 445 nm is NLT 95.0% and NMT 103.0% that of the *Standard solution*.
DOXORUBICIN HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP42–NF37*	1481	31-May-2019	1-Jun-2019	*NA*	*NA*	In the fourth equation in *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
EPRINOMECTIN	IMPURITIES/*Organic Impurities/Acceptance criteria*	*USP42–NF37*	1627	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Total unknown impurities*: Change NMT 1.0 to: NMT 1.0%

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SUMATRIPTAN	ADDITIONAL REQUIREMENTS/*USP Reference Standards* <11>	*USP42–NF37*	4139	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Sumatriptan Succinate Related Impurities RS: Change Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1*H*-indol-5-yl]-*N*-methylmethane sulfonamide maleate salt, sumatriptan succinate related compound C, [3-[2-(dimethylamino-*N*-oxide)ethyl]-1*H*-indol-5-yl]-*N*-methylmethane sulfonamide, and [3-[2-(aminoethyl)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]-1*H* -indo l-5-yl]-*N*-methyl methanesulfona mide. to: Mixture of sumatriptan succinate, [3-[2- (methylamino)et hyl]-1*H* -indo l-5-yl]-*N* -methylmethane sulfonamide, sumatriptan succinate related compound C, [3 -[2-(dimethylami no-*N* -o xid e)ethyl]-1*H* -indo l-5-yl]-*N* -methylmethane sulfonamide, and [3-[2-(amin oethyl)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]-1*H* -indo l-5-yl]-*N*-methyl methanesulfona mide.
BACILLUS COAGULANS	ASSAY/ *Enumeration*	*USP42–NF37*	4746	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Sample preparation* and *Analysis*: Change peptone water to: *Peptone diluent*
ARTICLES OF BOTANICAL ORIGIN	TEST FOR A FL ATO XINS/*Method I*	*USP42–NF37*	6701	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Aflatoxin standard solution*: Change ? = molecular absorptivity to: ? = molar absorptivity AND in paragraph 2 of *Aflatoxin standard solution*: Change transfer an accurate volume of each aflatoxin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard stock solution to: transfer an accurate volume of each aflatoxin stock solution
CETIRIZINE HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	897	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Cetirizine Related Compound A RS: Change 2-(2-{4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl}ethoxy)acetic acid, ethyl ester dihydrochloride. $C_{23}H_{29}ClN_2O_3 \cdot 2HCl$ 489.86 to: (*RS*)-2-[2-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic acid ethyl ester oxalate. C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{23}H_{29}ClN_2O_3 \cdot C_2H_2O_4$ 506.98
DIPHENHYDRAMINE HYDROCHLORIDE AND IBUPROFEN CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Analysis*	*USP42–NF37*	1402	31-May-2019	1-Jun-2019	*NA*	*NA*	Change C_S = concentration of USP Diphenhydramine Hydrochloride RS and USP Ibuprofen RS in the *Standard solution* (mg/mL) to: C_S = concentration of USP Diphenhydramine Hydrochloride RS or USP Ibuprofen RS in the *Standard solution* (mg/mL)
DULOXETINE DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Test 3*/*Procedure*: Change 1 N sodium hydroxide VS. to: 0.1 N

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloric acid VS.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- …
- Next page Next ›
- Last page Last »